Souhaitez-vous accéder aux communiqués récents ?

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human...

New programs expand a growing suite of AI offerings, delivered in flexible formats designed to meet leaders where they are

Octopus Apollo VCT plc Final Results Octopus Apollo VCT plc today announces the final results for the year ended 31 January 2026. Octopus Apollo VCT plc (‘Apollo’ or the ‘Company’) is a Venture...

    ICG plc21 May 2026Final ResultsFor the financial year ended 31 March 2026Highlights Strategic and AUM Delivering significant growth from flagship and scaling strategies, maintaining disciplined...

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its...

 AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422...

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue...

Company announcement – No. 14 / 2026 Zealand Pharma Announces Financial Results for the First Three Months of 2026 A defining start to 2026, marked by pivotal progress for leading obesity assets,...

CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...